Huang Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Huang Huang has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Jin Zhu
Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237 (China)
6 shared publicationsHualiang Jiang
Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237 (China)
4 shared publications- Jian Li
State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
4 shared publications Yong Xu
Humanwell Healthcare (Group) Co. Ltd, 666 Gaoxin Road, East Lake High-tech Development Zone, Wuhan 430075, China
4 shared publicationsXu Shen
Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China
3 shared publicationsHongzhi Miao
Department of Pathology, University of Michigan, Ann Arbor, USA
2 shared publications
Latest Publications
- 30 November 2023
- Published by World Scientific Pub Co Pte Ltd in Journal of Medical Robotics Research
- Vol. 08 (03n04)
Robot-Assisted Vascular Shunt Insertion with the dVRK Surgical Robot
Vascular shunt insertion is a common surgical procedure performed to restore blood flow to damaged tissues temporarily. It usually requires a surgeon and a surgical assistant. We consider three scenarios: (1) a surgeon is available locally; (2) a remote surgeon is available via teleoperation; (3) no surgeon is available. In each scenario, a minimally invasive surgical-assistant da Vinci robot operates in a different mode either by teleoperation or automation. Robotic assistance for this procedure is challenging due to precision and control uncertainty. The role of the robot in this task depends on the availability of a human surgeon. We propose a trimodal framework for vascular shunt insertion assisted by a da Vinci Research Kit (dVRK) robotic surgical assistant (RSA). To help further study for the community, we also present a physics-based simulated environment for shunt insertion built on top of the NVIDIA Isaac ORBIT simulator. We collect a large dataset of trajectories for the shunt insertion environment using ORBIT and implement these trajectories to show the simulator’s realism, showcasing the possibility for future work to use the simulator for policy learning. Physical experiments demonstrate a success rate of 65–100% for mode (1), 100% for mode (2), and 75–95% for mode (3) across vessel phantoms with different sizes, color, and material properties. For dataset and videos, see https://sites.google.com/berkeley.edu/ravsi .
- 30 November 2023
- Published by World Scientific Pub Co Pte Ltd in Journal of Medical Robotics Research
- Vol. 08 (03n04)
Robot-Assisted Vascular Shunt Insertion with the dVRK Surgical Robot
Vascular shunt insertion is a common surgical procedure performed to restore blood flow to damaged tissues temporarily. It usually requires a surgeon and a surgical assistant. We consider three scenarios: (1) a surgeon is available locally; (2) a remote surgeon is available via teleoperation; (3) no surgeon is available. In each scenario, a minimally invasive surgical-assistant da Vinci robot operates in a different mode either by teleoperation or automation. Robotic assistance for this procedure is challenging due to precision and control uncertainty. The role of the robot in this task depends on the availability of a human surgeon. We propose a trimodal framework for vascular shunt insertion assisted by a da Vinci Research Kit (dVRK) robotic surgical assistant (RSA). To help further study for the community, we also present a physics-based simulated environment for shunt insertion built on top of the NVIDIA Isaac ORBIT simulator. We collect a large dataset of trajectories for the shunt insertion environment using ORBIT and implement these trajectories to show the simulator’s realism, showcasing the possibility for future work to use the simulator for policy learning. Physical experiments demonstrate a success rate of 65–100% for mode (1), 100% for mode (2), and 75–95% for mode (3) across vessel phantoms with different sizes, color, and material properties. For dataset and videos, see https://sites.google.com/berkeley.edu/ravsi .
- 27 May 2023
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 18 (7) , 725-735
Covalent drug discovery using sulfur(VI) fluoride exchange warheads
Covalent drug discovery has traditionally focused on targeting cysteine, but the amino acid is often absent in protein binding sites. This review makes the case to move beyond cysteine labeling using sulfur (VI) fluoride exchange (SuFEx) chemistry to expand the druggable proteome. Recent advances in SuFEx medicinal chemistry and chemical biology are described, which have enabled the development of covalent chemical probes that site-selectively engage amino acid residues (including tyrosine, lysine, histidine, serine, and threonine) in binding pockets. Areas covered include chemoproteomic mapping of the targetable proteome, structure-based design of covalent inhibitors and molecular glues, metabolic stability profiling, and synthetic methodologies that have expedited the delivery of SuFEx modulators. Despite recent innovations in SuFEx medicinal chemistry, focused preclinical research is required to ensure the field moves from early chemical probe discovery to the delivery of transformational covalent drug candidates. The authors believe that covalent drug candidates designed to engage residues beyond cysteine using sulfonyl exchange warheads will likely enter clinical trials in the coming years.
- 27 May 2023
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 18 (7) , 725-735
Covalent drug discovery using sulfur(VI) fluoride exchange warheads
Covalent drug discovery has traditionally focused on targeting cysteine, but the amino acid is often absent in protein binding sites. This review makes the case to move beyond cysteine labeling using sulfur (VI) fluoride exchange (SuFEx) chemistry to expand the druggable proteome. Recent advances in SuFEx medicinal chemistry and chemical biology are described, which have enabled the development of covalent chemical probes that site-selectively engage amino acid residues (including tyrosine, lysine, histidine, serine, and threonine) in binding pockets. Areas covered include chemoproteomic mapping of the targetable proteome, structure-based design of covalent inhibitors and molecular glues, metabolic stability profiling, and synthetic methodologies that have expedited the delivery of SuFEx modulators. Despite recent innovations in SuFEx medicinal chemistry, focused preclinical research is required to ensure the field moves from early chemical probe discovery to the delivery of transformational covalent drug candidates. The authors believe that covalent drug candidates designed to engage residues beyond cysteine using sulfonyl exchange warheads will likely enter clinical trials in the coming years.
- 31 August 2020
- Published by Springer Nature in Nature Chemical Biology
- Vol. 16 (12) , 1403-1410
Covalent inhibition of NSD1 histone methyltransferase
The nuclear receptor-binding SET domain (NSD) family of histone methyltransferases is associated with various malignancies, including aggressive acute leukemia with NUP98-NSD1 translocation. While NSD proteins represent attractive drug targets, their catalytic SET domains exist in autoinhibited conformation, presenting notable challenges for inhibitor development. Here, we employed a fragment-based screening strategy followed by chemical optimization, which resulted in the development of the first-in-class irreversible small-molecule inhibitors of the nuclear receptor-binding SET domain protein 1 (NSD1) SET domain. The crystal structure of NSD1 in complex with covalently bound ligand reveals a conformational change in the autoinhibitory loop of the SET domain and formation of a channel-like pocket suitable for targeting with small molecules. Our covalent lead—compound BT5—demonstrates on-target activity in NUP98-NSD1 leukemia cells, including inhibition of histone H3 lysine 36 dimethylation and downregulation of target genes, and impaired colony formation in an NUP98-NSD1 patient sample. This study will facilitate the development of the next generation of potent and selective inhibitors of the NSD histone methyltransferases.
- 31 August 2020
- Published by Springer Nature in Nature Chemical Biology
- Vol. 16 (12) , 1403-1410
Covalent inhibition of NSD1 histone methyltransferase
The nuclear receptor-binding SET domain (NSD) family of histone methyltransferases is associated with various malignancies, including aggressive acute leukemia with NUP98-NSD1 translocation. While NSD proteins represent attractive drug targets, their catalytic SET domains exist in autoinhibited conformation, presenting notable challenges for inhibitor development. Here, we employed a fragment-based screening strategy followed by chemical optimization, which resulted in the development of the first-in-class irreversible small-molecule inhibitors of the nuclear receptor-binding SET domain protein 1 (NSD1) SET domain. The crystal structure of NSD1 in complex with covalently bound ligand reveals a conformational change in the autoinhibitory loop of the SET domain and formation of a channel-like pocket suitable for targeting with small molecules. Our covalent lead—compound BT5—demonstrates on-target activity in NUP98-NSD1 leukemia cells, including inhibition of histone H3 lysine 36 dimethylation and downregulation of target genes, and impaired colony formation in an NUP98-NSD1 patient sample. This study will facilitate the development of the next generation of potent and selective inhibitors of the NSD histone methyltransferases.
- Top Cited PapersOpen Access
- 17 December 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (2) , 981-997
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
The protein-protein interaction between menin and Mixed Lineage Leukemia 1 (MLL1) plays a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in the Nucleophosmin 1 (NPM1) gene. As a step toward clinical translation of menin-MLL1 inhibitors, we report development of MI-3454, a highly potent and orally bioavailable inhibitor of the menin-MLL1 interaction. MI-3454 profoundly inhibited proliferation and induced differentiation in acute leukemia cells and primary patient samples with MLL1 translocations or NPM1 mutations. When applied as a single agent, MI-3454 induced complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia, including patient-derived xenograft models, through downregulation of key genes involved in leukemogenesis. We also identified MEIS1 as a potential pharmacodynamic biomarker of treatment response with MI-3454 in leukemia, and demonstrated that this compound is well tolerated and did not impair normal hematopoiesis in mice. Overall, this study demonstrates for the first time profound activity of the menin-MLL1 inhibitor as a single agent in clinically relevant PDX models of leukemia. These data provide a strong rationale for clinical translation of MI-3454 or its analogs for leukemia patients with MLL1-rearrangements or NPM1 mutations
- 17 December 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (2) , 981-997
Top Cited PapersOpen AccessMenin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
The protein-protein interaction between menin and Mixed Lineage Leukemia 1 (MLL1) plays a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in the Nucleophosmin 1 (NPM1) gene. As a step toward clinical translation of menin-MLL1 inhibitors, we report development of MI-3454, a highly potent and orally bioavailable inhibitor of the menin-MLL1 interaction. MI-3454 profoundly inhibited proliferation and induced differentiation in acute leukemia cells and primary patient samples with MLL1 translocations or NPM1 mutations. When applied as a single agent, MI-3454 induced complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia, including patient-derived xenograft models, through downregulation of key genes involved in leukemogenesis. We also identified MEIS1 as a potential pharmacodynamic biomarker of treatment response with MI-3454 in leukemia, and demonstrated that this compound is well tolerated and did not impair normal hematopoiesis in mice. Overall, this study demonstrates for the first time profound activity of the menin-MLL1 inhibitor as a single agent in clinically relevant PDX models of leukemia. These data provide a strong rationale for clinical translation of MI-3454 or its analogs for leukemia patients with MLL1-rearrangements or NPM1 mutations
- 12 August 2015
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 17 (10) , 4715-4719
I−/TBHP catalyzed Csp3–N/Csp2–N bond formation via oxidative coupling with benzophenone imine in water
An I−/TBHP catalyzed oxidative amination with benzophenone imine under environmentally benign conditions was developed to afford primary amines and amides.
- 12 August 2015
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 17 (10) , 4715-4719
I−/TBHP catalyzed Csp3–N/Csp2–N bond formation via oxidative coupling with benzophenone imine in water
An I−/TBHP catalyzed oxidative amination with benzophenone imine under environmentally benign conditions was developed to afford primary amines and amides.
- 15 May 2015
- Published by Wiley in ChemMedChem
- Vol. 10 (7) , 1184-1199
Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism
Farnesoid X receptor (FXR) plays an important role in the regulation of cholesterol, lipid, and glucose metabolism. Recently, several studies on the molecular basis of FXR antagonism have been reported. However, none of these studies employs an FXR antagonist with nonsteroidal scaffold. On the basis of our previously reported FXR antagonist with a trisubstituted isoxazole scaffold, a novel nonsteroidal FXR ligand was designed and used as a lead for structural modification. In total, 39 new trisubstituted isoxazole derivatives were designed and synthesized, which led to pharmacological profiles ranging from agonist to antagonist toward FXR. Notably, compound 5s (4′‐[(3‐{[3‐(2‐chlorophenyl)‐5‐(2‐thienyl)isoxazol‐4‐yl]methoxy}‐1H‐pyrazol‐1‐yl)methyl]biphenyl‐2‐carboxylic acid), containing a thienyl‐substituted isoxazole ring, displayed the best antagonistic activity against FXR with good cellular potency (IC50=12.2±0.2 μM). Eventually, this compound was used as a probe in a molecular dynamics simulation assay. Our results allowed us to propose an essential molecular basis for FXR antagonism, which is consistent with a previously reported antagonistic mechanism; furthermore, E467 on H12 was found to be a hot‐spot residue and may be important for the future design of nonsteroidal antagonists of FXR.
- 15 May 2015
- Published by Wiley in ChemMedChem
- Vol. 10 (7) , 1184-1199
Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism
Farnesoid X receptor (FXR) plays an important role in the regulation of cholesterol, lipid, and glucose metabolism. Recently, several studies on the molecular basis of FXR antagonism have been reported. However, none of these studies employs an FXR antagonist with nonsteroidal scaffold. On the basis of our previously reported FXR antagonist with a trisubstituted isoxazole scaffold, a novel nonsteroidal FXR ligand was designed and used as a lead for structural modification. In total, 39 new trisubstituted isoxazole derivatives were designed and synthesized, which led to pharmacological profiles ranging from agonist to antagonist toward FXR. Notably, compound 5s (4′‐[(3‐{[3‐(2‐chlorophenyl)‐5‐(2‐thienyl)isoxazol‐4‐yl]methoxy}‐1H‐pyrazol‐1‐yl)methyl]biphenyl‐2‐carboxylic acid), containing a thienyl‐substituted isoxazole ring, displayed the best antagonistic activity against FXR with good cellular potency (IC50=12.2±0.2 μM). Eventually, this compound was used as a probe in a molecular dynamics simulation assay. Our results allowed us to propose an essential molecular basis for FXR antagonism, which is consistent with a previously reported antagonistic mechanism; furthermore, E467 on H12 was found to be a hot‐spot residue and may be important for the future design of nonsteroidal antagonists of FXR.
- 1 January 2015
- Published by Elsevier in Tetrahedron Letters
- Vol. 56 (4) , 586-589
A highly efficient approach to unnatural amino-acids containing 3-hydroxyoxindole skeleton via a one-pot, three-component procedure
- 1 January 2015
- Published by Elsevier in Tetrahedron Letters
- Vol. 56 (4) , 586-589
A highly efficient approach to unnatural amino-acids containing 3-hydroxyoxindole skeleton via a one-pot, three-component procedure
- 24 November 2014
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 14 (19) , 2175-2187
Recent Advances in Non-Steroidal FXR Antagonists Development for Therapeutic Applications
Farnesoid X receptor (FXR, NR1H4), a nuclear receptor (NR) highly expressed in the liver, intestine, kidney, adrenal glands and other cholesterol-rich tissues, functions as the master regulator for bile acid homeostasis. FXR, which regulates the expression of genes encoding proteins involved in cholesterol homeostasis, plays an essential role in regulating cholesterol, lipid, and glucose metabolism. Recently, some FXR agonists are reported to have low selectivity on NRs, which forces the researchers to move their eyes onto the development of FXR antagonists with high selectivity. The development of non-steroidal FXR antagonists with different scaffolds including AGN34, tuberatolides, atractylenolides, andrographolides, GW4064 derivatives and 1,3,4-trisubstitutedpyrazolones, provides us a prospect for the therapy of in ammation, metabolic syndrome, diabetes, cholesterol gallstones, and cancer.
- 24 November 2014
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 14 (19) , 2175-2187
Recent Advances in Non-Steroidal FXR Antagonists Development for Therapeutic Applications
Farnesoid X receptor (FXR, NR1H4), a nuclear receptor (NR) highly expressed in the liver, intestine, kidney, adrenal glands and other cholesterol-rich tissues, functions as the master regulator for bile acid homeostasis. FXR, which regulates the expression of genes encoding proteins involved in cholesterol homeostasis, plays an essential role in regulating cholesterol, lipid, and glucose metabolism. Recently, some FXR agonists are reported to have low selectivity on NRs, which forces the researchers to move their eyes onto the development of FXR antagonists with high selectivity. The development of non-steroidal FXR antagonists with different scaffolds including AGN34, tuberatolides, atractylenolides, andrographolides, GW4064 derivatives and 1,3,4-trisubstitutedpyrazolones, provides us a prospect for the therapy of in ammation, metabolic syndrome, diabetes, cholesterol gallstones, and cancer.
- 3 August 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (16) , 7037-7053
Discovery and Optimization of 1,3,4-Trisubstituted-pyrazolone Derivatives as Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonists
LBVS of 12480 in-house compounds, followed by HTRF assay, resulted in one nonsteroidal compound (11) with antagonistic activity against FXR (69.01 ± 11.75 μM). On the basis of 11, 26 new derivatives (12a–z) were designed and synthesized accordingly. Five derivatives (12f–g, 12p, 12u, and 12y) showed better antagonistic activities against FXR than compound 11. Remarkably, the most potent derivative, 12u (8.96 ± 3.62 μM), showed antagonistic capability approximately 10 times and 8-fold higher than that of the control (GS) and the starting compound 11, respectively. 12u was further confirmed to have high binding affinity with FXRαLBD, FXR specificity over six other nuclear receptors, and potent antagonistic activity against FXR in two cell testing platforms. 12u strongly suppressed the regulating effects of CDCA on FXR target genes. The therapeutic potential of 12u was identified by lowering the contents of triglyceride and cholesterol in human hepatoma HepG2 cells and in the cholesterol-fed C57BL/6 mices.
- 3 August 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (16) , 7037-7053
Discovery and Optimization of 1,3,4-Trisubstituted-pyrazolone Derivatives as Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonists
LBVS of 12480 in-house compounds, followed by HTRF assay, resulted in one nonsteroidal compound (11) with antagonistic activity against FXR (69.01 ± 11.75 μM). On the basis of 11, 26 new derivatives (12a–z) were designed and synthesized accordingly. Five derivatives (12f–g, 12p, 12u, and 12y) showed better antagonistic activities against FXR than compound 11. Remarkably, the most potent derivative, 12u (8.96 ± 3.62 μM), showed antagonistic capability approximately 10 times and 8-fold higher than that of the control (GS) and the starting compound 11, respectively. 12u was further confirmed to have high binding affinity with FXRαLBD, FXR specificity over six other nuclear receptors, and potent antagonistic activity against FXR in two cell testing platforms. 12u strongly suppressed the regulating effects of CDCA on FXR target genes. The therapeutic potential of 12u was identified by lowering the contents of triglyceride and cholesterol in human hepatoma HepG2 cells and in the cholesterol-fed C57BL/6 mices.
- 1 January 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (2) , 958-962
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent
- 1 January 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (2) , 958-962
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent